Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 11/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17479592 | 0.85 | MAPK1 (0.62) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL7230719 | 0.84 | MAPK1 (0.60) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL5113642 | 0.83 | MAPK1 (0.58) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL26927238 | 0.82 | MAPK1 (0.50) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL3217260 | 0.81 | ALPL (0.64) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL30107039 | 0.81 | MAPK1 (0.70) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL5111954 | 0.78 | GAA (0.56) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL7998000 | 0.78 | MAPK1 (0.53) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL68056 | 0.75 | MAPK1 (1.00) | MAPK1RAB9ANPC1GAAALPL | |
| SCHEMBL3216117 | 0.75 | MAPK1 (0.62) | MAPK1RAB9ANPC1GAAALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2980089-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-9637483-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160039811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2980089-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| CN-101282725-A | Therapeutic agent for diabetes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2008-10-08 | — | — | CN | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174682-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | MAPK1 23/4885RAB9A 1586/4885NPC1 4602/4885 |
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 851/4885RAB9A 3599/4885NPC1 1683/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 932/4885RAB9A 3729/4885NPC1 1377/4885 |
| US-20160039811-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | MAPK1 23/4885RAB9A 1586/4885NPC1 4602/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 851/4885RAB9A 3599/4885NPC1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.